PharmaCyte Biotech Inc - Asset Resilience Ratio
PharmaCyte Biotech Inc (PMCB) has an Asset Resilience Ratio of 0.67% as of January 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PMCB PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how PharmaCyte Biotech Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of PharmaCyte Biotech Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down PharmaCyte Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is PharmaCyte Biotech Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $372.25K | 0.67% |
| Total Liquid Assets | $372.25K | 0.67% |
Asset Resilience Insights
- Limited Liquidity: PharmaCyte Biotech Inc maintains only 0.67% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
PharmaCyte Biotech Inc Industry Peers by Asset Resilience Ratio
Compare PharmaCyte Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for PharmaCyte Biotech Inc (2009–2025)
The table below shows the annual Asset Resilience Ratio data for PharmaCyte Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-04-30 | 0.66% | $366.32K | $55.17 Million | -- |
| 2024-04-30 | 0.00% | $0.00 | $59.90 Million | -- |
| 2020-04-30 | 25.50% | $1.57 Million | $6.17 Million | +25.04pp |
| 2009-04-30 | 0.46% | $31.18K | $6.84 Million | -- |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including adv… Read more